Korean J Ophthalmol.  2020 Apr;34(2):168-169. .3341/kjo.2019.0071.

Subthreshold Micropulse Yellow Laser (577 nm) for Idiopathic Macular Telangiectasia Type 1 Resistant to Intravitreal Injection

• Kang YK
• Park HS

• KMID: 2507414
• DOI: http://doi.org/.3341/kjo.2019.0071

Figure

• 

  Fig. 1 Serial fundus photography, fluorescein angiography (FA), and spectral domain optical coherence tomography (SD-OCT) of the left eye. (A) Initial fundus photograph shows multiple aneurysmal capillary dilatations and large circinate hard exudates. FA shows aneurysmal telangiectasia in the juxtafoveal area. SD-OCT shows cystoid macular edema (CME). (B) After 2 applications of subthreshold micropulse yellow laser (SMYL), fundus photography shows resolution of aneurysms and exudates. SD-OCT shows improved CME. (C) Hard exudates are not seen on fundus photography, but FA shows aneurysms and telangiectatic vessels in the temporal parafoveal area (arrow) at 11 months after SMYL. SD-OCT shows recurrent CME. (D) At 1 month after the third SMYL treatment, there is no definite retinal damage on fundus photography, and the SD-OCT shows CME resolution. (E) Crystalline deposits and a few new aneurysms are seen on fundus photography. Retinal atrophy at the temporal macula is seen in the area of ablative laser application. SD-OCT shows improved CME but mild cystic changes.

Reference

1. Yannuzzi LA, Bardal AM, Freund KB, et al. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006; 124:450–460. PMID: 16606869.

2. Nowilaty SR, Al-Shamsi HN, Al-Khars W. Idiopathic juxtafoveolar retinal telangiectasis: a current review. Middle East Afr J Ophthalmol. 2010; 17:224–241. PMID: 20844678.

3. Lavinsky D, Wang J, Huie P, et al. Nondamaging retinal laser therapy: rationale and applications to the macula. Invest Ophthalmol Vis Sci. 2016; 57:2488–2500. PMID: 27159441.

4. Kim YJ, Kim SY, Ha S, et al. Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years. Eye (Lond). 2019; 33:819–825. PMID: 30610228.

5. Kowalczuk L, Matet A, Dirani A, et al. Efficacy of intravitreal aflibercept in macular telangiectasia type 1 is linked to the ocular angiogenic profile. Retina. 2017; 37:2226–2237. PMID: 28002269.